Merck beats forecast, but issues cautious 2013 view

Fri Feb 1, 2013 7:09am EST

Feb 1 (Reuters) - Merck & Co's quarterly results beat forecasts, helped by strong sales of its Januvia diabetes drug and Gardasil vaccine against cervical cancer, but the company issued a full-year 2013 profit view at the low end of Wall Street expectations

The No. 2 U.S. drugmaker on Friday said it earned $1.4 billion, or 46 cents per share, in the fourth quarter. That compared with $1.51 billion, or 49 cents per share, in the year-earlier period, when the company took charges for acquisition and restructuring expenses.